GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cann Group Ltd (ASX:CAN) » Definitions » Research & Development

Cann Group (ASX:CAN) Research & Development : A$2.10 Mil (TTM As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is Cann Group Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Cann Group's Research & Development for the six months ended in Dec. 2023 was A$0.38 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2023 was A$2.10 Mil.

Cann Group Research & Development Historical Data

The historical data trend for Cann Group's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cann Group Research & Development Chart

Cann Group Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Research & Development
Get a 7-Day Free Trial 1.05 1.28 2.03 2.99 4.29

Cann Group Semi-Annual Data
Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.95 2.04 2.57 1.72 0.38

Cann Group Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$2.10 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cann Group  (ASX:CAN) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Cann Group Research & Development Related Terms

Thank you for viewing the detailed overview of Cann Group's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Cann Group (ASX:CAN) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cann Group Ltd (ASX:CAN) » Definitions » Research & Development
Comparable Companies
ASX:NXS ASX:LGP ASX:ANP ASX:LV1 ASX:IVX ASX:EOF ASX:MVP ASX:ECS ASX:PXS ASX:IDT ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 SZSE:000538 XSWX:SDZ HKSE:03692
Traded in Other Exchanges
CNGGF:USA CVJ:Germany
Address
262-276 Lorimer Street, Port Melbourne, VIC, AUS, 3207
Website
https://www.canngrouplimited.com
Cann Group Ltd is engaged in the cultivation of medicinal cannabis for both medicinal and research purposes pursuant to the licenses and permits issued to the company; the development and manufacture (via third party arrangements) of finished product formulations; and the pursuit and execution of various supply and offtake agreements with third parties.